 HOUSTON, June 17, 2021 PRNewswire -- CNS Pharmaceuticals, Inc. NASDAQ: CNSP CNS or the Company, a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that as part of the annual reconstitution of the Russell stock indexes, CNS Pharmaceuticals has been selected to be added to the Russell 2000 Index effective June 25, 2021, after the close of the U.S. equity markets. John Climaco, CEO of CNS Pharmaceuticals, commented We are pleased to meet this noteworthy milestone and be included in the Russell 2000 Index. 